|
Market Cap (5-Jul) $8,036,723,200 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (19-Jun) 16,724,445 (4.94%) (48th) |
|
52w High $31.97 |
52w Low $17.03 |
P/E 54.95 |
EPS 0.14 |
TLX released this announcement to the ASX on 2 August 2022, 8:18. The announcement is marked as price sensitive, and is 3 page(s) in length and 254.31kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 2.044% short sold according to ASIC data. It was ranked the 118th most shorted stock on the ASX. It is now ranked as the 48th most shorted stock on the ASX with 4.944% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| APAC Regulatory Progress Prostate and Kidney Cancer Imaging | 2 August 2022, 8:18 |
| Appendix 4C and Activities Report for June 2022 Quarter | 21 July 2022, 9:08 |
| Kevin Richardson appointed as CEO, Telix Americas | 11 July 2022, 8:23 |
| Zircon Kidney Cancer Imaging Study completes Enrollment | 11 July 2022, 8:21 |
You must be logged in to post a reply.
Telix Pharmaceuticals 